BRPI0815503A2 - Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico - Google Patents

Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico

Info

Publication number
BRPI0815503A2
BRPI0815503A2 BRPI0815503-8A2A BRPI0815503A BRPI0815503A2 BR PI0815503 A2 BRPI0815503 A2 BR PI0815503A2 BR PI0815503 A BRPI0815503 A BR PI0815503A BR PI0815503 A2 BRPI0815503 A2 BR PI0815503A2
Authority
BR
Brazil
Prior art keywords
potassium
alivari
iir
modulating
disorder
Prior art date
Application number
BRPI0815503-8A2A
Other languages
English (en)
Inventor
Thomas Eugene Christos
George S Amato
Robert N Atkinson
Maria Graciela Barolli
Lilli Ann Wolf-Gouveia
Mark J Suto
Original Assignee
Icagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Icagen Inc filed Critical Icagen Inc
Publication of BRPI0815503A2 publication Critical patent/BRPI0815503A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
BRPI0815503-8A2A 2007-08-17 2008-08-18 Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico BRPI0815503A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95664007P 2007-08-17 2007-08-17
US7824108P 2008-07-03 2008-07-03
PCT/US2008/073519 WO2009026254A1 (en) 2007-08-17 2008-08-18 Heterocycles as potassium channel modulators

Publications (1)

Publication Number Publication Date
BRPI0815503A2 true BRPI0815503A2 (pt) 2014-09-30

Family

ID=40378578

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0815503-8A2A BRPI0815503A2 (pt) 2007-08-17 2008-08-18 Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico

Country Status (11)

Country Link
US (1) US8058274B2 (pt)
EP (1) EP2178373B1 (pt)
JP (1) JP5463287B2 (pt)
KR (1) KR20100044852A (pt)
CN (1) CN101842011A (pt)
AU (1) AU2008289101A1 (pt)
BR (1) BRPI0815503A2 (pt)
CA (1) CA2696631A1 (pt)
ES (1) ES2400604T3 (pt)
MX (1) MX2010001824A (pt)
WO (1) WO2009026254A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2008289101A1 (en) 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
US8431608B2 (en) * 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
JPWO2009128520A1 (ja) * 2008-04-18 2011-08-04 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有する複素環化合物
EP2338888A1 (en) * 2009-12-24 2011-06-29 Almirall, S.A. Imidazopyridine derivatives as JAK inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ カリウムイオンチャネル阻害剤としてのピロロピリダジン
CN105026399B (zh) * 2013-03-11 2017-06-23 百时美施贵宝公司 作为钾离子通道抑制剂的吡咯并三嗪类化合物
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
ES2526262B1 (es) * 2013-07-05 2015-10-15 Ángel TARAPIELLA CARREÑO Sistema de control de estacionamientos urbanos
WO2015039333A1 (en) * 2013-09-22 2015-03-26 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
EP3572405B9 (en) 2014-09-12 2023-12-06 Biohaven Therapeutics Ltd. Benzoimidazol-1,2-yl amides as kv7 channel activators
WO2018110669A1 (en) 2016-12-15 2018-06-21 Ono Pharmaceutical Co., Ltd. Activator of trek (twik related k+ channels) channels
JP2022521537A (ja) 2019-02-22 2022-04-08 ファースト・バイオセラピューティクス・インコーポレイテッド イミダゾピリジニル化合物及び増殖性障害の処置のためのその使用
CN114057641A (zh) * 2020-08-07 2022-02-18 上海挚盟医药科技有限公司 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用
CN115968362A (zh) * 2020-08-21 2023-04-14 第一生物治疗股份有限公司 作为pet放射性示踪剂的[18f]-标记的咪唑并吡啶衍生物
CN114478431A (zh) * 2022-03-09 2022-05-13 台州学院 一种双取代苯并噻吩类钾离子通道激动剂的制备方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3701780A (en) * 1970-09-18 1972-10-31 Merck & Co Inc Imidazo(1,2-a)pyridines
US4096264A (en) * 1975-12-09 1978-06-20 Merck & Co., Inc. Certain substituted imidazo [1,2-a] pyridines
GB8719368D0 (en) * 1987-08-15 1987-09-23 Wellcome Found Heterocyclic compounds
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
CA2311483A1 (en) * 2000-06-12 2001-12-12 Gregory N Beatch IMIDAZO [1,2-A] PYRIDINIC ETHERS AND USES THEREOF
AU2002232439A1 (en) * 2000-11-29 2002-06-11 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
US6939874B2 (en) * 2001-08-22 2005-09-06 Amgen Inc. Substituted pyrimidinyl derivatives and methods of use
US7632866B2 (en) 2002-10-21 2009-12-15 Ramot At Tel Aviv University Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
PL376822A1 (pl) * 2002-11-07 2006-01-09 Merck & Co., Inc. Pochodne fenyloalaniny jako inhibitory dipeptydylopeptydazy do leczenia lub zapobiegania cukrzycy
JP2007529496A (ja) * 2004-03-19 2007-10-25 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 抗菌剤としてのイミダゾピリジン及びイミダゾピリミジン誘導体
TW200633990A (en) * 2004-11-18 2006-10-01 Takeda Pharmaceuticals Co Amide compound
WO2007008769A2 (en) * 2005-07-08 2007-01-18 George Mason University Use of pseudan and pseudan inclusion bodies
US20070161645A1 (en) * 2005-11-02 2007-07-12 Targegen, Inc. Thiazole inhibitors targeting resistant kinase mutations
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
CL2007002261A1 (es) * 2006-08-04 2008-05-02 Takeda Pharmaceutical Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
EP2058309A4 (en) * 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
EP2063962A2 (en) * 2006-09-07 2009-06-03 Biogen Idec MA Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
US8431608B2 (en) * 2007-08-17 2013-04-30 Icagen Inc. Heterocycles as potassium channel modulators
AU2008289101A1 (en) 2007-08-17 2009-02-26 Icagen, Inc. Heterocycles as potassium channel modulators
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
WO2009136663A1 (en) 2008-05-08 2009-11-12 Takeda Pharmaceutical Company Limited Fused heterocyclic derivatives and use thereof

Also Published As

Publication number Publication date
EP2178373B1 (en) 2013-01-23
US20090062290A1 (en) 2009-03-05
EP2178373A1 (en) 2010-04-28
CA2696631A1 (en) 2009-02-26
US8058274B2 (en) 2011-11-15
ES2400604T3 (es) 2013-04-11
WO2009026254A1 (en) 2009-02-26
JP2010536796A (ja) 2010-12-02
MX2010001824A (es) 2010-04-21
KR20100044852A (ko) 2010-04-30
JP5463287B2 (ja) 2014-04-09
EP2178373A4 (en) 2011-10-19
CN101842011A (zh) 2010-09-22
AU2008289101A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
BRPI0815503A2 (pt) Composto, composição farmacêutica, e, métodos para modular a atividade de um canal de íon potássio em um indivíduo, para aumentar o fluxo de íon por meio de canais de potássio dependentes da voltagem em uma célula e para tratar, prevenir, inibir ou aliviar um distúrbio ou condição do sistema nervoso central ou periférico
BRPI0813311A2 (pt) Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
CL2007003005A1 (es) Compuestos derivados de [1,6]-naftiridinona, moduladores de la actividad cinasa; composicion farmaceutica que los comprende; y su uso para tratar trastornos proliferativos, inflamatorios, autoinmune, del sistema nervioso central, entre otros.
BRPI0906938A2 (pt) Ventilador, e, método e sistema configurado para fornecer um fluxo de gás para dispensação a uma via aérea de um indivíduo
MY175979A (en) Certain chemical entities, compositions and methods
BRPI0816050A2 (pt) composto, composição farmacêutica, e, métodos para inibir o caminho de hedgehog, e para reduzir a proliferação, diferenciação celulares e/ou afetar a modulação do microambiente estromático
BRPI0812740A2 (pt) composto, composição farmacêutica, uso do composto, e, método para tratamento, prevenção ou alívio de um distúrbio do sistema nervoso central de um corpo de animal vivo.
BRPI0907591A2 (pt) Compostos e composição farmacêutica como moduladores de atividade de gpr119, método in vitro para modulação da atividade de gpr119 e usos do referido composto, seus sais farmaceuticamente aceitáveis ou suas composições farmacêuticas.
TN2010000122A1 (en) Compounds and compositions as modulators of gpr119 activity
MX2009009491A (es) Compuestos y composiciones como moduladores de la actividad del gpr119.
WO2010008995A3 (en) Controlled-release apoptosis modulating compositions and methods for the treatment of otic disorders
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
BRPI0620113A2 (pt) métodos de modulação da atividade de um canal iônico introduzido, e de tratamento de um distúrbio, e, composto
BRPI0811993A2 (pt) " hetarilanilinas como moduladores para beta-amiloide ".
BRPI0818244A2 (pt) Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
WO2010034015A3 (en) Modulating the alternative complement pathway
WO2009132050A3 (en) Auris formulations for treating otic diseases and conditions
BRPI0812452A2 (pt) Meio de distribuição com ajustador de dose travável e válvula de uma via
WO2012106536A3 (en) Systems, tip assemblies, methods and kits for introducing material into cells
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BRPI0816881A2 (pt) Composto, composição farmacêutica, uso de um composto, e, métodos para tratar doenças ou distúrbios e para preparar um composto.
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0915382A2 (pt) composto, composição farmacêutica, e, método para tratar uma doença ou um distúrbio.
BRPI0812515A2 (pt) Micro-organismo com sistema de vitamina b12 desregulado
BRPI0812368A2 (pt) Sistemas de liberação de droga transdérmica do tipo matriz e respectivo método de preparação.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.